Table 1 Formulary listings for DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists in the Canadian provinces in October 2018
From: Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom
AB | BC | MB | NS | ON | QC | SK | ||
|---|---|---|---|---|---|---|---|---|
DPP-4 inhibitors | Alogliptin | NL | NL | NL | NL | NL | R | NL |
Alogliptin + metformin | NL | NL | NL | NL | NL | R | NL | |
Linagliptin | R | R | R | R | L | R | R | |
Linagliptin + metformin | R | R | R | R | L | R | R | |
Sitagliptin | R | DL | R | R | L | R | R | |
Sitagliptin+ metformin | R | DL | R | R | L | R | R | |
Sitagliptin + ertugliflozin | NL | NL | NL | NL | NL | NL | NL | |
Saxagliptin | R | R | R | R | L | R | R | |
Saxagliptin + metformin | R | R | R | R | L | R | R | |
SGLT-2 inhibitors | Canagliflozin | R | NL | R | R | L | R | R |
Canagliflozin + metformin | NL | NL | NL | NL | NL | NL | NL | |
Dapagliflozin | R | NL | R | R | L | R | R | |
Dapagliflozin + metformin | R | NL | R | R | L | R | R | |
Empagliflozin | R | NL | R | R | R | R | R | |
Empagliflozin + metformin | NL | NL | NL | NL | NL | R | NL | |
GLP-1 receptor agonists | Albiglutide | NL | NL | NL | NL | NL | NL | NL |
Dulaglutide | NL | NL | NL | NL | NL | NL | NL | |
Exenatide | NL | NL | NL | NL | NL | NL | NL | |
Liraglutide | NL | NL | NL | NL | NL | R | NL | |
Liraglutide + insulin degludec | NL | NL | NL | NL | NL | NL | NL | |
Lixisenatide | NL | NL | NL | NL | NL | R | NL | |
Lixisenatide + insulin glargine | NL | NL | NL | NL | NL | NL | NL | |
Semaglutide | NL | NL | NL | NL | NL | NL | NL |